Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug developmentBOSTON, March 13, 2018 – PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group (CHA) to enhance early phase clinical development in Korea.

The collaboration is designed to provide biopharmaceutical companies with comprehensive services that leverage PAREXEL’s global clinical research and regulatory expertise with CHA’s experience conducting…

Source: RealWire

Leave a Reply